Harpoon Therapeutics is an immuno-oncology company which uses a proprietary technology platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases. The Company has designed a novel antibody-based drug discovery platform called TriTAC™ that unleashes the target cell killing properties of a patient’s own immune system through T cell activation.
TriTAC™ antibodies are designed to simultaneously bind to cancer cells and T cells, causing the attached T cells to release toxic factors leading to destruction of the attached target cell. In addition, TriTAC™ antibodies are engineered to bind to human serum albumin which allows for less frequent dosing, and their relatively small size allows for improved penetration into tumor tissue.
|HQ||South San Francisco, CA, US||Map|
Market capitalization (11-May-2022)
Closing stock price (11-May-2022)
|USD||Q3, 2017||Q3, 2018||Q1, 2019||Q2, 2019||Q3, 2019||Q1, 2020||Q2, 2020||Q3, 2020|
Depreciation and Amortization
Cash From Operating Activities
When was Harpoon Therapeutics founded?
Harpoon Therapeutics was founded in 2015.
Who are Harpoon Therapeutics key executives?
Harpoon Therapeutics's key executives are Julie Eastland, Natalie R. Sacks and Susan Dana Jones.
How many employees does Harpoon Therapeutics have?
Harpoon Therapeutics has 45 employees.
Who are Harpoon Therapeutics competitors?
Competitors of Harpoon Therapeutics include Enara Bio, Aeglea and ImmunoGen.
Where is Harpoon Therapeutics headquarters?
Harpoon Therapeutics headquarters is located at 4000 Shoreline Ct #250, South San Francisco.
Where are Harpoon Therapeutics offices?
Harpoon Therapeutics has offices in South San Francisco and Louisville.
How many offices does Harpoon Therapeutics have?
Harpoon Therapeutics has 3 offices.
Receive alerts for 300+ data fields across thousands of companies